First new type of treatment for schizophrenia in decades - NPR
Sep 27, 2024 · The Food and Drug Administration approved Cobenfy, a twice-a-day medication that is a new kind of treatment for schizophrenia in adults.
FDA Approves Drug with New Mechanism of Action for Treatment …
Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first...
3 Things to Know About Cobenfy, the New Schizophrenia Drug > News …
2 days ago · Cobenfy is the first of what could potentially be several new medications that target receptors in the brain other than dopamine. Similar drugs are still in or may soon be in clinical testing phases. Cobenfy, which comes in a single capsule, is a combination of two drugs: xanomeline and trospium chloride. Xanomeline was tested in the late 1990s ...
FDA approves Bristol Myers Squibb's schizophrenia drug
Sep 26, 2024 · The Food and Drug Administration on Thursday approved Bristol Myers Squibb ’s highly anticipated schizophrenia drug Cobenfy, the first novel type of treatment for the debilitating, chronic mental...
FDA approves 1st new drug for schizophrenia in more than 30 years
Sep 26, 2024 · Cobenfy, manufactured by Bristol Myers Squibb, combines two drugs, xanomeline and trospium chloride, and is taken as a twice-daily pill. In clinical trials, this combination helped manage symptoms such as hallucinations, delusions, and disorganized thinking, which are common in schizophrenia.
FDA Approves the First New Schizophrenia Drug in Decades
Sep 27, 2024 · The FDA approved Cobenfy as a monotherapy—meaning it is meant to be taken alone, without other medications—but more studies will be needed to see how the medication works in combination with ...
U.S. Food and Drug Administration Approves Bristol Myers …
Sep 27, 2024 · U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults.
FDA Approves Cobenfy, a New Kind of Drug for Schizophrenia
Sep 27, 2024 · Cobenfy (xanomeline/trospium chloride) could bring patients what they've long hoped for: A means of easing the hallucinations and "voices" that disrupt their lives without the weight gain and sluggishness of current dopamine-focused drugs.
Breakthrough treatment for schizophrenia | News | Wellcome
Sep 27, 2024 · Now, a new combination drug called Cobenfy has been approved by the US Food and Drug Administration (FDA). It is the first new pharmacological approach for treating schizophrenia in over 50 years and may provide an alternative …
FDA Approves Revolutionary Schizophrenia Drug - WebMD
Sept. 27, 2024 – In a breakthrough for people living with schizophrenia, the FDA has approved a new oral medication for adults. Unlike traditional antipsychotic drugs, the medication, which will be...